Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
J. vasc. bras ; 22: e20230018, 2023. graf
Article in English | LILACS-Express | LILACS | ID: biblio-1521171

ABSTRACT

Abstract A 100-year-old male patient was admitted with a ruptured abdominal aortic aneurysm due to type IA endoleak. Given the proximity of the ruptured site to the superior mesenteric artery (SMA) and renal arteries, a ChEVAR was indicated. Catheterization of the target visceral vessels was a challenging procedural step because of an intensely tortuous thoracic aorta. This hostile aortic anatomy also inhibited exchange for a super stiff guide-wire and selective cannulation with the diagnostic catheter was repeatedly lost when guidewire exchange was attempted. To overcome this issue, a 5 x 40 mm balloon catheter was placed 3cm into the target arteries. The balloon was then inflated below the nominal pressure limit enabling safe exchange for a super stiff guidewire and placement of three 90-cm long 7Fr guiding sheaths. The procedure was thus safely performed with deployment of an aortic extension and the bridging stents.


Resumo Um paciente de 100 anos foi diagnosticado com um aneurisma de aorta abdominal roto por um endoleak 1A. Pela proximidade do ponto de ruptura com a artéria mesentérica superior (AMS) e as artérias renais, um ChEVAR foi indicado. A cateterização das artérias-alvo foi um passo desafiador pela intensa tortuosidade da aorta torácica. Essa anatomia aórtica hostil também impediu a troca por um fio-guia extra-rígido, e a cateterização seletiva foi repetidamente perdida quando a troca de fio-guia foi tentada. Para superar essa dificuldade, um cateter balão 5mm x 40mm foi posicionado nas artérias-alvo. O balão foi, então, insuflado abaixo da pressão nominal, permitindo uma troca segura do fio-guia por um fio-guia extra-rígido e o posicionamento de três bainhas longas 7Frx 90cm. Assim, o procedimento foi executado de forma segura, com o implante de uma extensão aórtica e dos stents recobertos.

2.
Einstein (Säo Paulo) ; 13(2): 189-195, Apr-Jun/2015. tab, graf
Article in English | LILACS | ID: lil-751433

ABSTRACT

ABSTRACT Objective: To characterize a chronic hepatitis B cohort based on initial and follow-up clinical evaluations. Methods: A retrospective and descriptive analysis of clinical and laboratory data from chronic HBsAg adult carriers, without HIV, unexposed to treatment, with at least two outpatient visits, between February 2006 and November 2012. Fisher´s exact test, χ², Wilcoxon, Spearman, multiple comparisons and Kappa tests were applied, the level of significance adopted was 5%, with a 95% confidence interval. Results: 175 patients with mean age of 42.95±12.53 years were included: 93 (53.1%) were men, 152 (86.9%) were negative for hepatitis B e-antigen (HBeAg), 3 (1.7%) had hepatitis C coinfection, 15 (8.6%) had cirrhosis, and 2 (1.1%) had hepatocellular carcinoma. Genotype A predominated. Sixty-six patients (37.7%) had active hepatitis, 6 (3.4%) presented immune tolerance, and 38 (21.7%) were inactive carriers. Exacerbations and/or viral breakthrough were detected in 16 patients (9.1%). In 32 patients (18.3%), hepatitis B virus DNA remained persistently elevated and alanine aminotransferase levels were normal, whereas in 17 (9.7%), there was low hepatitis B virus DNA and alterated alanine aminotransferase. If only initial alanine aminotransferase and hepatitis B virus DNA values were considered, 15 cases of active hepatitis would not have been detected. Advanced fibrosis was more common in HBeAg-positive patients, and it was significantly associated with transaminases, hepatitis B virus DNA, and age. Conclusion: Many patients had active hepatitis, but almost 25%, who were HBeAg non-reactive, were only identified because of combined analyses of the hepatitis B virus DNA and transaminases levels, sometimes associated with histological data, after clinical follow-up. .


RESUMO Objetivo: Caracterizar uma coorte de pacientes com hepatite B crônica, segundo parâmetros iniciais e evolutivos. Métodos: Análise retrospectiva e descritiva dos dados clínicos e laboratoriais de portadores crônicos adultos do HBsAg, sem HIV, virgens de tratamento, com ao menos duas consultas ambulatoriais entre fevereiro de 2006 a novembro de 2012. Empregaram-se os testes exato de Fisher, χ², Wilcoxon, Spearman, Kappa e comparações múltiplas, o nível de significância estatística adotado foi de 5% e intervalo de confiança de 95%. Resultados: Foram incluídos 175 pacientes com média de idade de 42,95±12,53 anos, 93 (53,1%) do sexo masculino, 152 (86,9%) não reagentes para o antígeno e (HBeAg), 3 (1,7%) coinfectados com hepatite C, 15 (8,6%) cirróticos e 2 (1,1%) com carcinoma hepatocelular. Predominou o genótipo A. Constataram-se hepatite ativa em 66 pacientes (37,7%), imunotolerância em 6 (3,4%), estado de portador inativo em 38 (21,7%), exacerbações e/ou escapes virais em 16 (9,1%). Em 32 (18,3%), havia DNA viral persistentemente elevado e alanina aminotransferase normal; em 17 (9,7%), carga viral constantemente baixa e alanina aminotransferase alterada. Se fossem considerados apenas transaminases e DNA viral iniciais, 15 casos de hepatite ativa não teriam sido evidenciados. Fibrose avançada foi mais prevalente em HBeAg reagentes e associou-se direta e significativamente ao DNA do vírus da hepatite, idade e transaminases. Conclusão: Grande parte dos pacientes apresentou hepatite ativa. Porém, aproximadamente um quarto (todos pertencentes ao grupo HBeAg não reagente) foram identificados somente em função da análise conjunta das mensurações sequenciais de DNA do vírus da hepatite e transaminases, por vezes aliada a dados histológicos, após seguimento. .


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Hepatitis B virus/genetics , Hepatitis B, Chronic/pathology , Liver Cirrhosis/pathology , Liver/pathology , Alanine Transaminase/blood , Biopsy , Cohort Studies , Carrier State/blood , Disease Progression , DNA, Viral/genetics , Follow-Up Studies , Genotype , Hepatitis B e Antigens/analysis , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Liver Cirrhosis/immunology , Medical Records , Outpatients , Retrospective Studies , Viral Load
3.
Rev. bras. epidemiol ; 13(4): 677-688, Dec. 2010. tab
Article in Portuguese | LILACS | ID: lil-569108

ABSTRACT

INTRODUÇÃO: Atualmente, a abordagem nutricional desempenha papel essencial no tratamento de pessoas que vivem com HIV/aids, particularmente no caso de alterações metabólicas pelo uso da terapia antirretroviral (TARV) que podem estar associadas ao maior risco de doenças cardiovasculares (DCV). OBJETIVO: Caracterizar o estado nutricional, clínico e a qualidade da dieta de pessoas que vivem com HIV/aids. METODOLOGIA: Trata-se de um estudo transversal envolvendo pessoas que vivem com HIV/aids em atendimento na rede de serviços especializados no município de São Paulo. Os usuários desta rede, em uso ou não de TARV, foram recrutados no período de dezembro de 2004 a maio de 2006, durante consultas de rotina. Foram coletados dados sociodemográficos, clínicos, bioquímicos, antropométricos e dietéticos. A qualidade da dieta foi avaliada segundo escores de padrão de consumo predominantemente "não protetor" e "protetor" para DCV. RESULTADOS: A amostra foi constituída por 238 pacientes em TARV e 76 sem TARV. A média dos níveis de colesterol total, triglicérides e glicemia foram maiores no grupo TARV (p < 0,001). A maior parte dos participantes do estudo, com e sem TARV, apresentava-se eutrófica, com média de índice de massa corporal 24,4 (± 4,3) e 24,3 (± 3,5) kg/m², respectivamente. A relação cintura-quadril foi maior entre homens em TARV que entre aqueles sem TARV (0,90 ± 0,06 versus 0,87 ± 0,05) (p < 0,001). O grupo em TARV apresentou média de escores indicativa de maior consumo de alimentos "não protetores" para DCV (p = 0,001). CONCLUSÃO: Foram evidenciadas condições nutricionais e metabólicas indesejáveis entre aqueles em TARV, predisponentes ao risco de DCV. É apontada a necessidade de direcionamento das intervenções em saúde a pessoas que vivem com HIV/aids, para o controle dos fatores associados a essas doenças antes do desfecho final.


INTRODUCTION: Nutrition currently plays a key role in the treatment of people living with HIV/AIDS (PLHA), especially in the case of metabolic alterations due to highly active antiretroviral therapy (HAART), which could be related to cardiovascular diseases (CD). OBJECTIVE: to describe the nutritional and clinical status, and the quality of diet of PLHA. METHODS: It is a cross-sectional study involving a network of ambulatory care facilities for PLHA in the city of São Paulo, Brazil. Patients, in use of HAART or not, were selected from December 2004 to may 2006, through routine clinic visits. We collected: socio-demographic, clinical, biochemical, anthropometric measures and dietary data. Diet quality was evaluated according to a "protecting" or "non-protecting" pattern of consumption scores for CD. RESULTS: The sample had 238 patients on HAART and 76 without treatment. Mean serum levels of total cholesterol, triglycerides and glucose were higher in the HAART group (p < 0.001). The majority of patients of both the treated and untreated group were eutrophic with a mean body mass index (BMI) of 24.4 (± 4.3) kg/m² and 24.3 (± 3.5), respectively. The waist-hip ratio was higher among men on HAART (0.90 ± 0.06 versus 0.87±0.05) (p < 0.001). The HAART group showed a mean food pattern score indicating a higher consumption of "non-protecting" foods for CD (p = 0.001). CONCLUSION: The results showed undesired nutritional and metabolic conditions among patients on HAART associated with CD. It is necessary to manage health intervention programs for PLHA in order to control cardiovascular risk factors before final outcomes.


Subject(s)
Adult , Female , Humans , Male , Diet , Health Status , HIV Infections , Nutritional Status , Ambulatory Care , Antiretroviral Therapy, Highly Active , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/physiopathology , Brazil , Cross-Sectional Studies , HIV Infections/drug therapy , HIV Infections/physiopathology , Urban Health
4.
Arq. bras. cardiol ; 93(2): 113-118, ago. 2009. tab
Article in English, Spanish, Portuguese | LILACS | ID: lil-528302

ABSTRACT

FUNDAMENTO: Desde o advento da AIDS, a terapia antiretroviral desenvolveu-se significantemente, incluindo a terapia antiretroviral altamente ativa (HAART) e a doença adquiriu uma característica crônica. Entretanto, após a introdução da HAART, várias alterações metabólicas foram observadas, principalmente relacionadas ao perfil lipídico. OBJETIVO: Avaliar e comparar os perfis lipídicos, analisar o risco cardiovascular, e descrever a prevalência da síndrome metabólica em pacientes com AIDS tratados ou não com HAART. MÉTODOS: Durante um período de 18 meses, 319 pacientes tratados em ambulatórios na cidade de São Paulo, Brasil, foram selecionados. RESULTADOS: A amostra final incluiu 215 pacientes tratados com HAART e 69 pacientes virgens de tratamento com HAART. A idade média era 39,5 anos, e 60,9 por cento eram do sexo masculino. Os principais fatores de risco cardiovascular eram o fumo (27 por cento), hipertensão (18 por cento) e histórico familiar de aterosclerose (40 por cento). Os valores médios de colesterol total, HDL-colesterol, triglicérides e glicose foram mais altos no grupo HAART do que no grupo não-HAART (205 vs 180 mg/dl, 51 vs 43 mg/dl, 219 vs 164 mg/dl e 101 vs 93 mg/dl respectivamente; p < 0,001 para todos). De acordo com o escore de risco de Framingham, o risco cardiovascular era moderado a alto em 11 por cento dos pacientes tratados com HAART e 4 por cento dos pacientes não-HAART. De acordo com a definição do Adult Treatment Panel III, a síndrome metabólica foi observada em 13 por cento e 12 por cento dos pacientes, respectivamente, com e sem HAART. CONCLUSÃO: Embora os valores médios do colesterol total, HDL-c e triglicérides tenham sido mais altos no grupo HAART, um maior risco cardiovascular não foi identificado no primeiro grupo. A prevalência de síndrome metabólica foi comparável em ambos os grupos.


BACKGROUND: Since the advent of AIDS, the anti-HIV therapy has developed significantly, including the highly active antiretroviral therapy (HAART) and the disease acquired a chronic characteristic. However, after the introduction of HAART, several metabolic alterations were observed, mainly related to the lipid profile. OBJECTIVES: to evaluate and compare lipid profiles, analyze cardiovascular risk, describe the prevalence of metabolic syndrome in AIDS patients with or without HAART. METHODS: Over an 18-month period, 319 patients treated at outpatient clinics in the city of São Paulo, Brazil were selected. RESULTS: The final sample included 215 patients receiving HAART and 69 HAART-naive patients. The mean age was 39.5 years, and 60.9 percent were males. The main cardiovascular risk factors were smoking (27 percent), hypertension (18 percent) and family history of atherosclerosis (40 percent). Mean total cholesterol, HDL-cholesterol, triglycerides and glucose were higher in the HAART group than in the non-HAART group (205 vs 180 mg/dl, 51 vs 43 mg/dl, 219 vs 164 mg/dl and 101 vs 93 mg/dl respectively; p < 0.001 for all). According to the Framingham risk score, the cardiovascular risk was moderate to high in 11 percent of the patients receiving HAART and 4 percent of the HAART-naïve patients. According to the Adult Treatment Panel III definition, the metabolic syndrome was observed in 13 percent and 12 percent of the patients with or without HAART, respectively. CONCLUSIONS: Although the mean values for total cholesterol, HDL-c and triglycerides were higher in the HAART group, a higher cardiovascular risk was not identified in the former. The prevalence of metabolic syndrome was comparable in both groups.


FUNDAMENTO: Desde el surgimiento del SIDA, la terapia antiretroviral se desarrolló significantemente. Al incluir la terapia antiretroviral altamente activa (HAART), la enfermedad adquirió una característica crónica. Sin embargo, tras la introducción de HAART, diversas alteraciones metabólicas se observaron, principalmente relacionadas al perfil lipídico. OBJETIVO: Evaluar y comparar los perfiles lipídicos, analizar el riesgo cardiovascular, y describir la prevalencia del síndrome metabólico en pacientes con SIDA tratados o no con HAART. MÉTODOS: Durante un período de 18 meses, se seleccionaron a 319 pacientes tratados en ambulatorios en la ciudad de São Paulo, Brasil. RESULTADOS: La muestra final incluyó a 215 pacientes tratados con HAART y a 69 pacientes vírgenes de tratamiento con HAART. La edad promedio era de 39,5 años, y el 60,9 por ciento eran del sexo masculino. Los principales factores de riesgo cardiovascular eran el fumo (27 por ciento), hipertensión (18 por ciento) e histórico familiar de aterosclerosis (40 por ciento). Los valores promedios de colesterol total, HDL-colesterol, triglicéridos y glucosa fueron más altos en el Grupo HAART que en el Grupo no-HAART (205 vs. 180 mg/dL, 51 vs. 43 mg/dL, 219 vs. 164 mg/dL, 101 vs. 93 mg/dL respectivamente; p < 0,001 para todos). De conformidad con el score de riesgo de Framingham, el riesgo cardiovascular era moderado y alto en el 11 por ciento de los pacientes tratados con HAART y el 4 por ciento de los pacientes no-HAART. Según la definición del Adult Treatment Panel III, el síndrome metabólico se observó en el 13 por ciento y el 12 por ciento de los pacientes, respectivamente, con y sin HAART. CONCLUSIÓN: Aunque los valores promedios del colesterol total, HDL-c y triglicéridos fueron más altos en el Grupo HAART, un mayor riesgo cardiovascular no se identificó en el primer grupo. La prevalencia de síndrome metabólico fue comparable en ambos grupos.


Subject(s)
Adult , Female , Humans , Male , Acquired Immunodeficiency Syndrome/drug therapy , Antiretroviral Therapy, Highly Active/adverse effects , Cardiovascular Diseases/etiology , Lipids/blood , Metabolic Syndrome/epidemiology , Acquired Immunodeficiency Syndrome/blood , Acquired Immunodeficiency Syndrome/complications , Atherosclerosis/complications , Brazil/epidemiology , Cross-Sectional Studies , Hypertension/complications , Metabolic Syndrome/chemically induced , Risk Factors , Smoking/adverse effects
5.
Braz. j. infect. dis ; 13(1): 18-23, Feb. 2009. tab
Article in English | LILACS | ID: lil-517810

ABSTRACT

Encephalitis caused by Toxoplasma gondii is the most common cause of central nervous system damage in patients with acquired immunodeficiency syndrome (AIDS). Toxoplasma may infect any of the brain cells, thus leading to non-specific neurotoxoplasmosis clinical manifestations including focused or non-focused signs and symptoms of central nervous system malfunction. Clinical development ranges from insidious display during weeks to experiencing acute general confusion or ultimately fatal onset. Cerebral toxoplasmosis occurs in advanced stages of immunodeficiency, and the absence of anti-toxoplasmosis antibodies by the immunofluorescence method does not allow us to rule out its diagnosis. As specific therapy begins, diagnosis confirmation is sought through clinical and radiological response. There are few accurate diagnosis methods to confirm such cases. We present a method for T. gondii DNA detection by real time PCR-Multiplex. Fifty-one patients were evaluated; 16 patients had AIDS and a presumptive diagnosis for toxoplasmosis, 23 patients were HIV-positive with further morbidities except neurotoxoplasmosis, and 12 subjects were HIV-negative control patients. Real time PCR-Multiplex was applied to these patients' cephalorachidian liquid with a specific T. gondii genome sequence from the 529bp fragment. This test is usually carried out within four hours. Test sensitivity, specificity, positive predictive value, and negative predictive value were calculated according to applicable tables. Toxoplasma gondii assay by real time Multiplex of cephalorachidian fluid was positive for 11 out of 16 patients with AIDS and a presumptive diagnosis for cerebral toxoplasmosis, while none of the 35 control patients displayed such a result. Therefore, this method allowed us to achieve 68.8 percent sensitivity, 100 percent specificity, 100 percent positive predictive value, and 87.8 percent negative predictive value. Real time PCR on CSF allowed high specificity...


Subject(s)
Adult , Animals , Female , Humans , Male , Middle Aged , AIDS-Related Opportunistic Infections/diagnosis , DNA, Protozoan/cerebrospinal fluid , Polymerase Chain Reaction/methods , Toxoplasma/genetics , Toxoplasmosis, Cerebral/diagnosis , AIDS-Related Opportunistic Infections/cerebrospinal fluid , Case-Control Studies , Predictive Value of Tests , Sensitivity and Specificity , Toxoplasmosis, Cerebral/cerebrospinal fluid
6.
In. Rosenblatt, Charles; Wroclawiski, Eric Roger; Lucon, Antonio Marmo; Pereyra, Elsa Aida Gay. HPV na prática médica. São Paulo, Atheneu, 2005. p.183-192, tab.
Monography in Portuguese | LILACS | ID: lil-441619
7.
In. Cimerman, Sérgio; Cimerman, Benjamim. Condutas em infectologia. São Paulo, Atheneu, 2004. p.55-62, tab.
Monography in Portuguese | LILACS, SES-SP | ID: lil-407396
10.
São Paulo med. j ; 117(6): 266-73, Nov. 1999.
Article in English | LILACS | ID: lil-252289

ABSTRACT

OBJECTIVE: To report on the importance of intestinal parasites in patients with AIDS, showing relevant data in the medical literature, with special emphasis on epidemiology, diagnosis and treatment of enteroparasitosis, especially cryptosporidiasis, isosporiasis, microsporidiasis and strongyloidiasis. DESIGN: Narrative review


Subject(s)
Humans , Male , AIDS-Related Opportunistic Infections/epidemiology , Intestinal Diseases, Parasitic/epidemiology , Acquired Immunodeficiency Syndrome/epidemiology , Strongyloidiasis , Prevalence , Giardiasis , Coccidiosis , Cryptosporidiosis , Amebiasis , Intestinal Diseases, Parasitic/diagnosis , Isospora
11.
Braz. j. infect. dis ; 3(4): 134-8, Aug. 1999. tab
Article in English | LILACS | ID: lil-254767

ABSTRACT

Serology is the primary means for identifying patients with HIV infection and Acquired Immunodeficiency Syndrome (AIDS). Testing of serum by serologic methods has been extensively used since 1985, not only for clinical diagnosis but also for epidemiological surveillance and donor screening in blood banks. Fast serological diagnostic techniques are now being developed, using urine and oral fluid, as an alternative for anti-HIV antibody screening, and many parallel studies are proving its accuracy. The purpose of this study was to evaluate the sensitivity, specificity,accuracy, positive predictive value (PPV) and negative predictive value(NPV) of the ImmunoComb II HIV 1&2 Saliva test from Orgenics(Dot-ELISA) compared to the routine exams (ELISA and Western Blot) of HIV positive/ AIDS patients, undergoing antiretroviral treatment or not, in different stages of the disease's evulution, and compared to serologic testing of known HIV negative patients by the use of serum ELISA (blood donors). To accomplish this, patients of the Immunogenic Deficiencies Control Center (CCDI) and voluntary blood donors of the Blood Bank Center of the Medical School of Säo Paulo/Federal University of Säo Paulo(EPM-UNIFESP) were evaluated. Sensitivity of Dot-ELISA in oral fluid was 100 percent, specificity 97.08 percent, PPV 96.66 percent and NPV 100 percent. The method used in this case study was shown to be highly sensitive and specific, being useful particularly epedemiological sur veillance and screening.


Subject(s)
Humans , Male , Female , Acquired Immunodeficiency Syndrome , Blood Donors , HIV Antibodies/immunology , Immunocompromised Host/immunology , Saliva/immunology , Urine , Blotting, Western , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Health Surveillance , Immunoblotting , Predictive Value of Tests , Risk Groups
12.
Rev. Soc. Bras. Med. Trop ; 32(2): 181-5, mar.-abr. 1999. tab
Article in Portuguese | LILACS | ID: lil-235189

ABSTRACT

Estudo transversal em 200 pacientes portadores da síndrome da imunodeficiência adquirida (AIDS) na cidade de Säo Paulo, a fim de verificar se a presença de enteroparasitas está associada aos diversos fatores de risco para a infecçäo pelo HIV. Verificou-se que a diarréia foi mais freqüente no grupo que apresentou parasitose intestinal, sendo a diferença altamente significante (p < 0,000 1). O parasita mais prevalente foi a Giardia lamblia em 32 (16 por cento) casos. A associaçäo entre a presença de parasitas nas fezes e os fatores de risco näo revelou significado estatístico, principalmente para os patógenos Giardia lamblia e Cryptosporidium parvum (p = 0,99; p = 0,69, respectivamente). Devido à divergência na literatura, convém realizar estudos em outras áreas geográficas do país


Subject(s)
Humans , Male , Adult , Acquired Immunodeficiency Syndrome , Entamoeba/parasitology , Intestinal Diseases, Parasitic/complications , Giardia lamblia/parasitology , Cross-Sectional Studies , Diarrhea/epidemiology , Sexual Behavior
15.
Sao Paulo; Univerdade Federal de Säo Paulo; 1997. 132 p.
Monography in Portuguese | LILACS, SES-SP | ID: lil-313093
16.
RBM rev. bras. med ; 49(1/2): 32-5, jan.-fev. 1992. tab
Article in Portuguese | LILACS | ID: lil-102433

ABSTRACT

A antibioticoterapia, utilizada para o tratamento de processos infecciosos severos, leva o paciente a permanecer hospitalizado por longo período. Isto aumenta os riscos de morbidade e mortalidade, além do custo para paciente e instituiçäo. Os autores discutem a possibilidade de introduzir tratamento ambulatorial para os pacientes que apresentem infecçöes de moderada a severas e que estejam em condiçöes clínicas e hemodinâmicas estáveis. Säo analisados 30 pacientes (27 casos de pielonefrite e três casos de pneumonia). A ceftriaxona, uma cefalosporina de terceira geraçäo, foi a droga de escolha para o tratamento e sua administraçäo foi feita ambulatorialmente via intramuscular, uma dose única ao dia. Em poucos casos foi necessário um breve período de internaçäo que näo ultrapassou, em média, dois dias. A taxa de cura foi de 100%. Näo foram observados efeitos adversos. Os autores concluem que os resultados mostram a eficácia e segurança da ceftriaxona para uso ambulatorial em pacientes com infecçöes moderadas ou severas, devidamente selecionados segundo as condiçöes clínicas


Subject(s)
Humans , Female , Pregnancy , Adult , Middle Aged , Bacterial Infections , Ceftriaxone , Ceftriaxone/administration & dosage , Ceftriaxone/therapeutic use , Bacterial Infections/diagnosis , Bacterial Infections/drug therapy , Injections, Intramuscular , Microbial Sensitivity Tests , Pneumonia/drug therapy , Prospective Studies , Pyelonephritis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL